

Force Family Office  
April 23, 2025

OTCQB: "SIGY"



Jim Joyce  
CEO, Inventor

## FORWARD-LOOKING STATEMENTS

The following presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Sigyn Therapeutics, Inc. ("Sigyn"). All statements in this presentation, other than statements of historical fact, are forward-looking statements within the meaning of federal securities laws. In some cases, you can identify forward-looking statements by terms such as "may," "will," "expect," "plan," "anticipate," "strategy," "designed," "intend," "believe," "estimate," "target," or "potential" and other similar expressions. Forward-looking statements involve risks, uncertainties and assumptions that may cause Sigyn's actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements in this presentation, including risks and uncertainties inherent in Sigyn's business and other risks described in Sigyn's filings with the Securities and Exchange Commission (SEC). Sigyn's forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading "Risk Factors" in Sigyn's periodic reports filed with the SEC, which are available on the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Sigyn undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

A close-up photograph of a medical device, likely a blood purifier or dialyzer. It features a clear plastic cylindrical body with a textured surface. A red tube is connected to the top via a blue plastic fitting. A white tube with a yellow connector is attached to the side. The background is blurred, showing more of the device and tubing.


## Next-Generation Blood Purification Therapies

### End-Stage Renal Disease (ESRD) Endotoxemia & Inflammation

- 550,000+ ESRD patients receive ~85 million dialysis treatments in the U.S. each year
- Annual mortality rate is ~20%
- Cardiovascular Disease & Sepsis are leading causes of early death
- Endotoxemia and concurrent inflammation underly these conditions



## THERAPEUTIC SOLUTION




*First-in-Mammal Studies at University of Michigan*

### Sigyn Therapy™

Broad-Spectrum Clearance of:

- Inflammatory Cytokines
- Bacterial Toxins (including endotoxin)
- Viral Pathogens

## THERAPEUTIC SOLUTION



*First-in-Mammal Studies at University of Michigan*

### Sigyn Therapy™

#### Key Attributes

- Deployed on dialysis and CRRT machines already located in hospitals and clinics
- Highly Efficient – bloodstream processed ~15 times during a four-hour treatment
- Immense Capacity - incorporates adsorbent components with ~200,000 M<sup>2</sup> of surface area

## Potential Value to the Dialysis Industry?

## Two Organizations Dominate The U.S. Dialysis Industry





- ~200,000 U.S. ESRD patients
- Average annual revenue per-patient is ~\$60,000
- ~\$1 Billion of increased revenue per-month of extended ESRD patient life
- ~\$250 million in recouped revenues per-week of reduced hospitalization




- ~280,000 U.S. ESRD patients
- Average annual revenue per-patient is ~\$62,000
- ~\$1.45 Billion in increased revenue per-month of extended ESRD patient life
- ~\$362 million in recouped revenues per-week of reduced hospitalization




## Clinical Plan

- Submit “Breakthrough Device” application to FDA
- Investigation Device Exemption (IDE) drafted for FDA submission
- Feasibility study protocol to enroll 12-15 ESRD subjects at three site locations
- Sigyn Therapy administered in series with regular dialysis treatments
- Primary endpoint is safety / Secondary endpoints - change in endotoxin and inflammatory cytokine levels
- Value inflection point - completion of study sets stage for ESRD subject pivotal study and provides a potential pivotal pathway into non-ESRD indications

Feasibility Study Establishes Potential  
Pivotal Pathway into 3 Major-Markets



## Public Market Landscape for Blood Purification Therapies



### Sigyn Therapy™

Broad-Spectrum Clearance of:

- Bacterial Toxins (including endotoxin)
  - Spectral Medical (PMX Endotoxin removal)  
Current market value ~27x SIGY
- Inflammatory Cytokines
  - Cytosorbents (CytoSorb cytokine removal)  
Peak market value: ~100x SIGY
- Viral Pathogens
  - Aethlon Medical (Hemopurifier virus removal)  
Peak market value: ~30x SIGY



## Additional Sigyn Therapeutics Information

### The Sigyn Team

- Includes extracorporeal industry thought leaders across Management, our Board of Directors and Science Advisory Board

### Development Pipeline

- ChemoPure™ to reduce chemotherapy toxicity
- ChemoPrep™ to optimize chemotherapy delivery
- ImmunePrep™ to optimize delivery of immunotherapeutic antibodies

## Public Market Data

- OTCQB: SIGY
- Recent Price: \$4.15
- 52-Week Range: \$3.15 - \$6.34
- Shares Outstanding: 1,605,377
- >90% of Shares Outstanding held by management, two funds, and one angel investment group

To receive an offering memorandum, text your email address to 619-368-2000

## Convertible Note Offering

- Up to \$3.75 million of 10% notes convertible into SIGY common shares at \$4.00. 1-year term. 100% warrant coverage provided.
- Use of proceeds includes funding of feasibility study to treat endotoxemia and current inflammation in dialysis patients.

*Previously, the Company has raised \$5+ million through 10% convertible notes whose average conversion price was \$6.75 per share*





To receive an offering memorandum, text your  
email address to 619-368-2000

## Next-Generation Blood Purification Therapies

To receive an offering memorandum, text your email address to 619-368-2000



Q & A

Jim Joyce  
CEO, Inventor  
[jj@sigyntherapeutics.com](mailto:jj@sigyntherapeutics.com)

